Coherus Oncology (FRA:8C5) Growth Rank: 5 (As of Sep. 22, 2026) — 400% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8C5 Coherus Oncology Inc FRA:8C5
59 GF Score
Price €1.17
GF Value €0.89
! 7 Warning Signs
View Full Analysis

What is Coherus Oncology Growth Rank?

Coherus Oncology FRA:8C5 +4.17% 59 Growth Rank is 5 as of Sep. 22, 2026, which is 400% above its 10-year median of 1.00. GuruFocus rates FRA:8C5 with a GF Score™ of 59/100 and a GF Value™ of €0.89. The stock has 7 warning signs investors should review.

Coherus Oncology has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Coherus Oncology Growth Rank Related Terms

FRA:8C5 vs VYGR, KROS, DTIL: Growth Rank Comparison

For the Biotechnology subindustry, Coherus Oncology's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Growth Rank distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Growth Rank falls into.


FRA:8C5
59GF Score
Coherus Oncology Inc FRA:8C5
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
Coherus Oncology (FRA:8C5) has a Growth Rank of 5 as of Sep. 22, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Coherus Oncology and its competitors. This is 400% above median its historical median of 1.00. Over the past decade, Coherus Oncology's Growth Rank has ranged from 1.00 to 6.00.
Is Coherus Oncology's Growth Rank too high?
Coherus Oncology's current Growth Rank of 5 is 400% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. Overall, Coherus Oncology has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Growth Rank compare to VYGR and KROS?
Coherus Oncology's Growth Rank of 5 can be compared against companies in the Biotechnology industry. Historically, Coherus Oncology's own Growth Rank has ranged from 1.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Growth Rank is 5, which is 400% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Coherus Oncology (FRA:8C5) has a current Growth Rank of 5. The stock's GF Value™ is €0.89, compared to a current price of €1.17 — trading 31.1% above its estimated fair value. The current Growth Rank is 5, which is 400% above median its 10-year median of 1.00. Coherus Oncology's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Growth Rank is 5 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.17 is trading 31.1% above its estimated GF Value™ of €0.89.

Key valuation signals for FRA:8C5:

  • Growth Rank: 5 (400% above median its 10-year median of 1.00)
  • GF Value™: €0.89 vs. price of €1.17 (31.1% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
59GF Score

Get the complete analysis for FRA:8C5

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price
€0.89
GF Value